NASDAQ · SINT
Healthcare · Medical - Devices
$1.74
Up+$0.00 (+0.00%)
Updated Sep 9, 2026, 3:41 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SINT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning SINT.
SINT research
Company profile and research snapshot.
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 4, 2026 | Maxim Group | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 13, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | Ascendiant Capital | Buy | — |
| Dec 8, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification
SeekingAlpha · Aug 11, 2026
Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsKevin OntiverosEric Olson - CEO & Chairman of the...
Benzinga · Aug 11, 2026
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 13.64 percent. This is a 17.58 percent increase over losses of $(0.91) per share
Yahoo · Aug 5, 2026
LivaNova (LIVN) delivered earnings and revenue surprises of +16.67% and +2.90%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SINT.
